Madrigal Pharmaceuticals Option Alert: Oct 17 $300 Calls at the Bid: 95 vs 1100 OI; Earnings 5/6 Before Open [est] 

Madrigal Pharmaceuticals Option Alert: Oct 17 $300 Calls at the Bid: 95 @ $86.8 vs 1100 OI; Earnings 5/6 Before Open [est] Ref=$345.765

Madrigal Pharmaceuticals Stock (NASDAQ: MDGL)

Madrigal Pharmaceuticals

MADRIGAL PHARMACEUTICALS INC

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

d-workday-photos-buildings-pleasanton-6110-int-4

News

Intraday Update

Markets

Movers

Trading Ideas

ACMR

ASPI

AXON

CEVA

COMM

FSLR

GSX Techedu Inc. American Depositary Shares

GOTU

HOOD

HURN

INTU

LNTH

MDGL

PRCH

SMCI

WDAY

XPEV

Workday, ACM Research, ZoomInfo Technologies, CEVA, Intuit And Other Big Stocks Moving Higher On Wednesday

Biotech

Earnings

Large Cap

Health Care

General

Madrigal&#39;s Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and revenue expectations.

Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis



Recent sales of a little-known stock, Madrigal Pharmaceuticals (NASDAQ:MDGL), could bode well for Novo Nordisk A/S (NYSE:NVO). The pharma industry giant has seen explosive sales growth for its GLP-1 agonist drug,

Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals Inc

Press Releases

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Management

Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

Alkermes

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Genmab

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Nuvalent

Vaxcyte

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

United Therapeutics Corporation - Common Stock

Comments

Madrigal Pharmaceuticals

Unusual Options Activity for

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga